Listed

Phathom Pharmaceuticals, Inc.: Form 10-Q for the period ended Mar 31, 2022

Filed with the SEC on May 10, 2022 and accepted by EDGAR at May 10, 2022, 08:16 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2022-01-01 to 2022-03-31$17.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-01-01 to 2022-03-31−$37.9mus-gaap:OperatingIncomeLoss
Interest expense3 months2022-01-01 to 2022-03-31$2.8mus-gaap:InterestExpense
Net income3 months2022-01-01 to 2022-03-31−$40.7mus-gaap:NetIncomeLoss
Operating cash flow3 months2022-01-01 to 2022-03-31−$45.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2022-01-01 to 2022-03-31$67.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-03-31$138.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-03-31$145.7mus-gaap:AssetsCurrent
Total assetsAt period end2022-03-31$149.0mus-gaap:Assets
Current liabilitiesAt period end2022-03-31$11.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-03-31$111.0mus-gaap:Liabilities
Long-term debtAt period end2022-03-31$91.0mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2022-03-31$38.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0000950170-22-008741. Last ingested by Listed: Nov 11, 2026, 03:04 ET. Listed shows no prices and gives no investment advice.